Regardless of who wins the US presidency, it will be the Senate that determines what action, if any, the federal government takes to rein in rising drug prices, says SVB Leerink analyst Goeffrey Porges.

Drugmakers have long depended on price increases to raise revenue, but those price hikes have slowed recently amid public scrutiny that is likely to continue, according to Leerink analyst Geoffrey Porges.

The FDA approved Sanofi and Regeneron Pharmaceuticals' eczema drug Dupixent as an adjunct treatment for certain people with asthma, potentially boosting sales by $2.5 billion, according to Leerink analyst Geoffrey Porges.

Sales of 45 best-selling drugs grew by 28% in the US, and 61% of that growth is attributable to price increases, according to a report by Leerink analyst Geoffrey Porges.

Drug manufacturers, despite public concern over high costs, continue to increase prices on selected drugs -- from 5% to 28% for Johnson & Johnson, 7.6% to 28% for Amgen and 10% to 16.5% for Gilead, according to Leerink analyst Geoffrey Porges.